Aurobindo Pharma’s arm gets marketing authorization for Zefylti

14 Feb 2025 Evaluate

Aurobindo Pharma’s wholly owned step-down subsidiary -- CuraTeQ Biologics s.r.o. has received marketing authorization from The European Commission (EC) in the European Union for Zefylti, a filgrastim biosimilar. 

Earlier in December 2024, the Committee for Medicinal Products (CHMP) of European Medicines Agency has adopted positive opinion recommending the approval of Zefylti.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1177.60 15.75 (1.36%)
10-Dec-2025 13:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.90
Dr. Reddys Lab 1253.70
Cipla 1494.85
Zydus Lifesciences 928.95
Lupin 2064.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×